Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Heteroaryl fused pyridines, pyrazines and pyrimidines as CRF1 receptor ligands

A heteroaryl group, CR10R11 technology, applied in drug combinations, pharmaceutical formulations, medical preparations containing active ingredients, etc., can solve the problems of anxiolytics and antidepressants that have yet to be fully elucidated, such as the mechanism of action and the position of action

Inactive Publication Date: 2006-12-13
NEUROGEN +1
View PDF0 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0007] The mechanism and location of traditional anxiolytics and antidepressants to produce medical effects are still to be fully elucidated

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Heteroaryl fused pyridines, pyrazines and pyrimidines as CRF1 receptor ligands
  • Heteroaryl fused pyridines, pyrazines and pyrimidines as CRF1 receptor ligands
  • Heteroaryl fused pyridines, pyrazines and pyrimidines as CRF1 receptor ligands

Examples

Experimental program
Comparison scheme
Effect test

example 1 2

[0359] Example 1. Dihydroxyboronic acid intermediate preparation method:

[0360] a.2-(dimethylamino)-4-methoxypyridine-5-dihydroxyboronic acid synthesis method

[0361]

[0362] Step A

[0363] Trifluoromethanesulfonic anhydride ( 12.9 g), triethylamine (8.4 g) was added. The reaction mixture was stirred for 20 minutes, then allowed to warm to room temperature. The volatile components were evaporated in vacuo, then the residue was dissolved in EtOAc and washed sequentially with aqueous sodium bicarbonate, water and brine solution. The organic phase was separated, dried and evaporated in vacuo to yield 4-methoxy-pyridin-2-yl triflate. It was used in the next step without further purification.

[0364] Step B

[0365] Dissolve 4-methoxy-pyridin-2-yl trifluoromethanesulfonate (0.5 g) and dimethylamine (2.4 mL of a 2M solution in THF) in DMSO (7 mL) and heat at 40° C. one night. EtOAc was added to the reaction mixture, washed with brine solution. The organic phase was...

example 2

[0452] 5-(1-ethyl-propyl)-2-(2-methoxy-4-trifluoromethoxy-phenyl)-3,7-dimethyl-5H-pyrrolo[2,3- b] pyrazine synthesis method

[0453]

[0454] Step A

[0455] Take the above-mentioned 2-bromo-3-methyl-5-isopentylaminopyrazine (870 mg) and 2-methoxy-4-trifluoromethoxyphenyl dihydroxyboronic acid (796 mg) known from the literature Dissolve in DME (15 mL). After degassing, tetrakis(triphenylphosphine)palladium(0) (390 mg) was added. After a second degassing, 1 N sodium carbonate solution (6.74 mL) was added, at which time the reaction was heated to 80 °C for 6 hours. The yellow mixture was added to water (200 mL), extracted with DCM (3 x 100 mL), and dried over magnesium sulfate. Purification on silica gel yields the coupled product. LCMS: m / z 370.17 (M+H) +

[0456] Step B

[0457] The product of step A (205 mg) was dissolved in chloroform (10 mL), and NBS (99 mg) was added. After stirring for 10 min, the yellow mixture was added to water (100 mL), extracted with DCM ...

example 3

[0463] {5-[3-chloro-5-(1-ethyl-propyl)-7-methyl-5H-pyrrolo[2,3-b]pyrazin-2-yl]-4-ethyl-pyridine -2-yl}-dimethyl-amine

[0464]

[0465] Step A

[0466] The above 2-chloro-6-isoamylaminopyrazine (25.1 g) was dissolved in chloroform (450 mL), and NBS (47.1 g) was added in batches. After stirring for 30 min, the yellow mixture was added to water (400 mL) and saturated sodium bicarbonate (100 mL), extracted with DCM (3 x 200 mL), and dried over magnesium sulfate. The crude product was carried on to Step B without further purification. Rf = 0.57, hexane / ethyl acetate (10 / 1).

[0467] Step B

[0468] The crude product from Step A (28.37 g) and allyl bromide (20.6 mL) were dissolved in DMF (200 mL). Sodium hydride (4.76 g) was added in portions, and the reaction was stirred at room temperature for 5 hours. The mixture was added to water (500 mL), extracted with ethyl acetate / hexane (1 / 20, 3×300 mL). The combined organic layers were dried over magnesium sulfate and purified on...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

Substituted heteroaryl fused pyridine, pyrazine, and pyrimidine compounds that act as selective modulators of CRF 1 receptors are provided. These compounds are useful in the treatment of a number of CNS and periphereal disorders, particularly stress, anxiety, depression, cardiovascular disorders, and eating disorders. Methods of treatment of such disorders and well as packaged pharmaceutical compositions are also provided. Compounds of the invention are also useful as probes for the localization of CRF receptors and as standards in assays for CRF receptor binding. Methods of using the compounds in receptor localization studies are given.

Description

technical field [0001] The present invention relates to novel substituted heteroaryl fused pyridine, pyrazine and pyrimidine compounds with high selectivity and / or high affinity for CRF receptor (corticotropin releasing factor receptor). The present invention also relates to a pharmaceutical composition comprising these compounds and their use in the treatment of psychiatric and neurological disorders, including major depression, anxiety-related disorders, post-traumatic stress disorders, supranuclear palsy and feeding disorders, and the treatment of immune, cardiovascular or heart-related diseases and colon hypersensitivity related to mental disorders and stress. The present invention also relates to the use of these compounds as probes for localizing CRF receptors in cells and tissues. A preferred CRF receptor is the CRF1 receptor. Background technique [0002] Corticotropin-releasing factor (CRF) (a 41 amino acid) is a major physiological regulator derived from proenkep...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): C07D487/04C07D471/04C07D519/00A61K31/4985A61K31/437A61K31/4375A61P25/24A61P9/00
CPCC07D471/04C07D487/04A61P25/00A61P25/18A61P25/22A61P25/24A61P3/04A61P43/00A61P9/00A61K31/4353
Inventor P·葛R·F·霍瓦特L·Y·张Y·亚马古基B·凯泽X·张S·张H·赵S·约翰N·莫尔克罗夫特G·舒茨科
Owner NEUROGEN
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com